Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

Individual Treatment Effects: Implications for Research, Clinical Practice, and Policy

This research outlines a framework and policy considerations to help health care stakeholders understand when it is important take patients’ individual treatment responses into account when making treatment, coverage and policy decisions.

Increased funding for comparative effectiveness research (CER) has sharpened the interest in learning what works best, for whom, and under what specific clinical circumstances. The goal of CER is to provide patients, payers, clinicians and policymakers with information to assist them in making the best decisions about treatment options. Because not all patients respond in the same way, research findings, treatment decisions, clinical guidelines or coverage policies applied in a “one-size-fits-all” manner based upon the population “average” response may lead to less than ideal health outcomes.

According to the research, four factors were identified that indicate when it may be inappropriate to narrow treatment choices:

  • Consequences of treatment choice are high: There are more significant consequences associated with delaying the optimal treatment choices for some conditions than others. For example, a person suffering from hay fever may try several successive treatments before finding the right one, with no long-term impact, while a person facing acute organ failure may not have the luxury of time or the disease may progress irreversibly while other alternatives are tried.

  • Patient diversity exists: Patients with the same disease often vary in the symptoms they experience. For example, some patients with depression may have sadness, insomnia, or lack of interest in daily activities, whereas others also may have anxiety and agitation.

  • Treatment response is independent of other treatments: The similarity between a patient’s likely responses to the available treatments for a condition (level of “treatment independence”) may vary. Some patients may be very likely to have consistent responses to other treatments, but in other conditions response may vary even when treatments belong to the same or different classes of medicines.

  • Patient preferences vary: Dosing, tolerance of particular side effects, willingness to make necessary behavioral changes and other physical and lifestyle factors all can impact the suitability of a particular treatment regimen for an individual patient.

In addition to understanding when these differences are clinically important, the study also outlines policy recommendations that can help to ensure that the right treatment is delivered to the right patient:

  • Researchers should conduct studies to better understand when, why and how much individual treatment differences matter. When patient response varies, researchers should directly compare treatment alternatives in the same patients. To understand when and why individual patients respond differently, researchers should pre-specify, collect and report individual patient characteristics and patient subgroups in their studies. Additional funding is needed for research to understand the impact of patient preferences on clinical and economic outcomes.

  • Payers should consider flexible coverage and reimbursement policies when individuals differ in their treatment response. When treatment response varies across patients, more flexible and broader coverage and reimbursement is needed. In addition, patients who differ from the population “average” due to their biology or prior response to treatment alternatives should not be required to pay higher out-of-pocket copayments.

  • Providers should ensure that clinical guidelines and patient care incorporate when, how and why individual patient treatment effects matter. Clinical guidelines and quality measures should take individual treatment effects into account.  Funding is needed for research and tools to help providers identify which treatments work best for “similar” patients, and for training to enhance provider-patient communication about an individual patient’s preferences and potential for benefits and risks. Mobile health (mhealth) and other systems can increase the knowledge available to providers and allow them to determine when alternative treatments are needed.
Blog Post

Optimizing the recipe for ‘health care spending pie’: Finding the most effective resource allocation

As health care costs continue to climb, rising 5.3 percent in 2015 and approaching 18 percent of the U.S. economy, it is more essential than ever to...
Blog Post

Are We Getting the Right Data to Make Individualized Health Decisions? Maybe.

Personalized medicine—an evolving field in which physicians use diagnostic tests to determine which medical treatments will work best for each...
Blog Post

CER Tweets of the Week: AHCJ CER Fellowships Announced; Latest Issue of JCER Published (August 8-12)

Last week, comparative effectiveness research stakeholders tweeted about the announcement of this year’s Association of Health Care Journalists CER...
Blog Post

CER Tweets of the Week: EBM in Elite Sports; Clinical Nuances (August 1 – August 5)

Last week, comparative effectiveness research stakeholders tweeted about a blog post published in BMJ (@BJSM_BMJ) that discusses the use of evidence...
Press Release

Data Can Offer Critical Insights, But Roadblocks to Data Access Persist

(Washington, D.C., April 1, 2016)—Data is key to improving health outcomes and creating efficiencies in our health care system, but a new study...
Press Release

Fit for Purpose? New NPC, AcademyHealth Framework Closes Gaps Between Payer Needs and Research Answers

(Washington, DC, September 21, 2015)—Despite multi-million dollar public and private investments to tap into big data and improve the evidence...
Press Release

NPC Comments on CMS’ Announcement to Allow Broader Access to Publicly Funded Databases

(Washington, DC, June 2, 2015)—The National Pharmaceutical Council (NPC) today commented on the Centers for Medicare and Medicaid Services’ (CMS)...
Press Release

State Medicaid Directors Share Views on Comparative Effectiveness Research And Its Impact on Policy in National Pharmaceutical Council Survey

(Washington, DC, April 16, 2015)—A new survey conducted on behalf of the National Pharmaceutical Council (NPC) shows that state Medicaid directors...
Commentary and Testimony Page

The Importance of Evidence, Value, Access and Innovation in 2016

Last year, in our 2015 Health Care Outlook published in Chain Drug Review, I highlighted the recent announcement by the U.S. Department of Health and...
Commentary and Testimony Page

Chain Drug Review – Commentary: “Health Care Outlook for 2015”

This commentary was originally published in the January 5, 2015 issue of Chain Drug Review.By: Dan Leonard, President, National Pharmaceutical...
Commentary and Testimony Page

NPC Comments on PCORI Proposal for Peer Review of Primary Research and Public Release of Research Findings

November 7, 2014Dr. Joe SelbyExecutive DirectorPatient-Centered Outcomes Research Institute1828 L St., NW, Suite 900Washington, DC 20036Dear Dr....
Commentary and Testimony Page

NPC Comments on CMS' Proposed Changes to Protected Classes

March 7, 2014Marilyn B. TavennerAdministratorCenters for Medicare & Medicaid ServicesU.S. Department of Health and Human Services200 Independence...
YouTube Videos

2016 Comparative Effectiveness Research and the Environment for Health Care Decision-Making

This one-hour webinar highlights the results of NPC's annual survey of comparative effectiveness research (CER) stakeholders and includes a panel...
YouTube Videos

When Is Evidence Fit for Purpose? Closing Gaps Between Researchers, Payers

Despite multi-million dollar public and private investments to tap into big data and improve the evidence available for health care decision-making,...
YouTube Videos

Comparative Effectiveness Research and the Environment for Health Care Decision-Making

During a March 26, 2015 webinar, the National Pharmaceutical Council discussed the results of its annual stakeholder survey on comparative...
YouTube Videos

Real-World Impact of Comparative Effectiveness Research Findings on Clinical Practice

National Pharmaceutical Council Chief Science Officer Robert W. Dubois, MD, PhD, discusses a peer-reviewed study suggesting that changes are needed...
Blog Post

Optimizing the recipe for ‘health care spending pie’: Finding the most effective resource allocation

As health care costs continue to climb, rising 5.3 percent in 2015 and approaching 18 percent of the U.S. economy, it is more essential than ever to...
Blog Post

Are We Getting the Right Data to Make Individualized Health Decisions? Maybe.

Personalized medicine—an evolving field in which physicians use diagnostic tests to determine which medical treatments will work best for each...
Blog Post

CER Tweets of the Week: AHCJ CER Fellowships Announced; Latest Issue of JCER Published (August 8-12)

Last week, comparative effectiveness research stakeholders tweeted about the announcement of this year’s Association of Health Care Journalists CER...
Blog Post

CER Tweets of the Week: EBM in Elite Sports; Clinical Nuances (August 1 – August 5)

Last week, comparative effectiveness research stakeholders tweeted about a blog post published in BMJ (@BJSM_BMJ) that discusses the use of evidence...

Got CER? Educating Pharmacists for Practice in the Future: New Tools for New Challenges

This study provides an early evaluation of the CER Collaborative's training program's impact on...

Data, Data Everywhere, But Access Remains a Big Issue for Researchers

This study captures the policy inconsistencies and hurdles that can hinder use of publicly funded...
cersurvey16

2016 Comparative Effectiveness Research and the Environment for Health Care Decision-Making

NPC's sixth annual survey of stakeholder views on comparative effectiveness research (CER) and the...
  •  
  • 1 of 18
  • >